Improving Outcomes for Patients With Diabetic Macular Edema.
| العنوان: | Improving Outcomes for Patients With Diabetic Macular Edema. |
|---|---|
| المؤلفون: | Puliafito CA, Dugel PU, Cousins SW, Packo KH, Eaton AM, Parrish RK 2nd, Kiss S, Reichel E |
| المصدر: | Ophthalmic surgery, lasers & imaging retina [Ophthalmic Surg Lasers Imaging Retina] 2015 Nov-Dec; Vol. 46 (10), pp. S5-S15. |
| نوع المنشور: | Interview |
| اللغة: | English |
| بيانات الدورية: | Publisher: Healio.com Country of Publication: United States NLM ID: 101599215 Publication Model: Print Cited Medium: Internet ISSN: 2325-8179 (Electronic) Linking ISSN: 23258160 NLM ISO Abbreviation: Ophthalmic Surg Lasers Imaging Retina Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2013-> : Thorofare, NJ : Healio.com Original Publication: Thorofare, NJ : Slack Incorporated [2013- ] |
| مواضيع طبية MeSH: | Laser Coagulation*, Angiogenesis Inhibitors/*therapeutic use , Diabetic Retinopathy/*therapy , Glucocorticoids/*therapeutic use , Macular Edema/*therapy, Blood Glucose/metabolism ; Blood Pressure ; Diabetic Retinopathy/diagnosis ; Humans ; Lipids/blood ; Macular Edema/diagnosis ; Patient Selection ; Risk Factors ; Treatment Outcome ; Vascular Endothelial Growth Factor A/antagonists & inhibitors |
| مستخلص: | Diabetic macular edema (DME) is one of the most common causes of vision loss in patients who have diabetes, and all of these patients are at risk for developing DME. The onset is often painless, difficult to detect, and can occur at any stage of diabetes. Ideally, DME is preventable, but treatment must be considered when preventative methods fail. Although physicians have several different treatment options for patients with DME, some patients who receive treatment can respond poorly and may even lose vision. Until recently, laser photocoagulation was regarded as the standard of care for DME; however, pharmaceutical treatments are rapidly replacing this standard as the desire to maximize systemic treatment of DME increases. A panel of experts gathered during the 2015 annual meeting of the Association for Research in Vision and Ophthalmology for a roundtable discussion designed to focus on improving outcomes for patients with DME using pharmaceutical treatment, including the use of anti-VEGFs and corticosteroids, based on the most current research and clinical data. (Copyright 2015, SLACK Incorporated.) |
| المشرفين على المادة: | 0 (Angiogenesis Inhibitors) 0 (Blood Glucose) 0 (Glucocorticoids) 0 (Lipids) 0 (VEGFA protein, human) 0 (Vascular Endothelial Growth Factor A) |
| تواريخ الأحداث: | Date Created: 20151215 Date Completed: 20160615 Latest Revision: 20151215 |
| رمز التحديث: | 20240628 |
| DOI: | 10.3928/23258160-20151124-01 |
| PMID: | 26653894 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2325-8179 |
|---|---|
| DOI: | 10.3928/23258160-20151124-01 |